These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26586608)

  • 21. Sequential designs with small samples: Evaluation and recommendations for normal responses.
    Nikolakopoulos S; Roes KC; van der Tweel I
    Stat Methods Med Res; 2018 Apr; 27(4):1115-1127. PubMed ID: 27342574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs).
    Wei B; Braun TM; Tamura RN; Kidwell KM
    Stat Med; 2018 Nov; 37(26):3723-3732. PubMed ID: 30010207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addressing sequential and concurrent treatment regimens in a small n sequential, multiple assignment, randomized trial (snSMART) in the MISTIC study.
    Cheng Y; Tremoulet A; Burns J; Jain S
    J Biopharm Stat; 2023 Dec; ():1-19. PubMed ID: 38095587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving the efficiency of estimation in randomized trials of adaptive treatment strategies.
    Lavori PW; Dawson R
    Clin Trials; 2007; 4(4):297-308. PubMed ID: 17848491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing cluster-level dynamic treatment regimens using sequential, multiple assignment, randomized trials: Regression estimation and sample size considerations.
    NeCamp T; Kilbourne A; Almirall D
    Stat Methods Med Res; 2017 Aug; 26(4):1572-1589. PubMed ID: 28627310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomization in substance abuse clinical trials.
    Hedden SL; Woolson RF; Malcolm RJ
    Subst Abuse Treat Prev Policy; 2006 Feb; 1():6. PubMed ID: 16722591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of sequentially randomized trials for testing adaptive treatment strategies.
    Ogbagaber SB; Karp J; Wahed AS
    Stat Med; 2016 Mar; 35(6):840-58. PubMed ID: 26412033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trials which randomize practices II: sample size.
    Kerry SM; Bland JM
    Fam Pract; 1998 Feb; 15(1):84-7. PubMed ID: 9527303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Goodness-of-fit processes for logistic regression: simulation results.
    Hosmer DW; Hjort NL
    Stat Med; 2002 Sep; 21(18):2723-38. PubMed ID: 12228887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.
    Thall P; Fox P; Wathen J
    Ann Oncol; 2015 Aug; 26(8):1621-8. PubMed ID: 25979922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size calculations for evaluating treatment policies in multi-stage designs.
    Dawson R; Lavori PW
    Clin Trials; 2010 Dec; 7(6):643-52. PubMed ID: 20630903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The direct assignment option as a modular design component: an example for the setting of two predefined subgroups.
    An MW; Lu X; Sargent DJ; Mandrekar SJ
    Comput Math Methods Med; 2015; 2015():210817. PubMed ID: 25649690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simulation study for evaluating the performance of response-adaptive randomization.
    Du Y; Wang X; Jack Lee J
    Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.